WallStSmart

Lineage, Inc. Common Stock (LINE)vsRayonier Inc (RYN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 455% more annual revenue ($5.37B vs $968.29M). RYN leads profitability with a 7.8% profit margin vs -3.1%. RYN earns a higher WallStSmart Score of 49/100 (D+).

LINE

Avoid

35

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: 0.67

RYN

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 3.7Quality: 7.5
Piotroski: 4/9Altman Z: 1.73

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

RYN2 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
272.1%10/10

Revenue surging 272.1% year-over-year

Areas to Watch

LINE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.7%3/10

Operating margin of 3.7%

Debt/EquityHealth
1.013/10

Elevated debt levels

RYN4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.734/10

Distress zone — elevated risk

Profit MarginProfitability
7.8%3/10

7.8% margin — thin

PEG RatioValuation
23.242/10

Expensive relative to growth rate

P/E RatioValuation
44.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : RYN

The strongest argument for RYN centers on Price/Book, Revenue Growth. Revenue growth of 272.1% demonstrates continued momentum.

Bear Case : LINE

The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.

Bear Case : RYN

The primary concerns for RYN are Altman Z-Score, Profit Margin, PEG Ratio. A P/E of 44.5x leaves little room for execution misses.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while RYN is a hypergrowth play — different risk/reward profiles.

RYN carries more volatility with a beta of 0.90 — expect wider price swings.

RYN is growing revenue faster at 272.1% — sustainability is the question.

LINE generates stronger free cash flow (186M), providing more financial flexibility.

Bottom Line

RYN scores higher overall (49/100 vs 35/100) and 272.1% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.

Visit Website →

Rayonier Inc

REAL ESTATE · REIT - SPECIALTY · USA

Rayonier is a leading timber real estate investment trust with assets located in some of the most productive softwood producing regions in the United States and New Zealand.

Want to dig deeper into these stocks?